Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Five Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials 27 Prominent Drugs 29 Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma 30 May 24, 2016: Novel immunotherapy trial for lymphoma offers hope to patients at Sylvester 30 May 18, 2016: ProNAi to Report Wolverine Phase 2 Interim Results on June 6th at ASCO 30 May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology 31 Apr 13, 2016: CTI BioPharma Announces Presentation on pixantrone at the American Association of Cancer Research Annual Meeting 31 Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-4948 at AACR Annual Meeting 32 Apr 06, 2016: MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma 32 Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 32 Mar 09, 2016: U.S. FDA Lifts Partial Clinical Hold on Medivation Pidilizumab 33 Mar 09, 2016: Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen 33 Mar 01, 2016: RedHill Biopharma Provides Update on YELIVA 34 Clinical Trial Profile Snapshots 35 Appendix 861 Abbreviations 861 Definitions 861 Research Methodology 862 Secondary Research 862 About GlobalData 863 Contact Us 863 Disclaimer 863 Source 864

List of Tables Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2016* 6 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13 Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 List of Figures Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13 Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 GlobalData Methodology 862

F. Hoffmann-La Roche Ltd. Celgene Corporation Johnson & Johnson Novartis AG AbbVie Inc. Amgen Inc. AstraZeneca Plc Bayer AG Takeda Pharmaceutical Company Limited Seattle Genetics, Inc.